$10.720
-0.809 (-7.55%)Zum Schluss
Kursprognosen
In der App öffnen, um Prognosen mit längerem Horizont freizuschalten.
Soll ich Retension Pharmaceuticals, Inc. Common Stock-Aktien kaufen?
Retension Pharmaceuticals may not be a good buy right now due to its current price of $11.44, which is significantly below the analyst's target of $55, but the recent 5-day decline of 19.66% raises concerns about short-term performance. The company has reported negative net income in the last four quarters, with a loss of $4,170,589 in Q2 2026, indicating ongoing financial struggles.
RTSN schloss am Thursday bei $10.72, nachdem der Kurs -7.55% fallen
Retension Pharmaceuticals, Inc. Common Stock (RTSN) last closed at $10.7200003, losing -7.55%. These facts feed the 1-day and 1-week RTSN price prediction above.
Prognose-Treiber
Die Prognose-Treiber von Retension Pharmaceuticals, Inc. Common Stock (RTSN) kombinieren ähnliche Chartmuster, Saisonalität und gleitende Durchschnitte.
Seasonality
Bearish
Saisonalitätsanalyse für RTSN
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.